Skip to main content
PBH
NYSE Life Sciences

Prestige Consumer Healthcare Files Pro Forma Financials for $1.045B Breathe Right Acquisition, Showing EPS Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$48.03
Mkt Cap
$2.275B
52W Low
$42.62
52W High
$81.65
52W Position info
13% above low
Off High info
41% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

PBH is trading near its 52-week low of $42.62 (13% above the low).

Summary

Prestige Consumer Healthcare has filed the pro forma financials for its $1.045 billion Breathe Right acquisition, detailing the financial impact including increased debt and diluted earnings per share.


Key Events · M&A and Partnerships · PBH

  • Acquisition Financials Released

    This 8-K/A provides the audited historical financials for the acquired OTC Wellness Business and unaudited pro forma combined financials for Prestige Consumer Healthcare Inc., fulfilling a prior undertaking.

  • Significant Debt Increase

    Long-term debt is projected to increase from $993.95 million to over $2.0 billion post-acquisition, reflecting the $1.045 billion term loan used to finance the acquisition.

  • EPS Dilution

    Pro forma basic earnings per share are estimated at $3.73, a decrease from the historical $3.93, primarily due to increased interest expense and acquisition accounting adjustments.

  • Revenue Growth

    Pro forma net sales are expected to increase to $1.28 billion from $1.08 billion, incorporating the acquired OTC Wellness Business's revenue.


Analysis · PBH · Life Sciences

This amended 8-K provides the detailed historical and pro forma financial statements for the recently completed $1.045 billion acquisition of the Breathe Right® brand and other OTC Wellness businesses. The pro forma financials reveal a significant increase in the company's debt burden and a dilutive impact on earnings per share, despite the expected revenue growth from the acquired assets. Investors will now be able to assess the full financial implications of this major acquisition on the company's balance sheet and profitability.

At the time of this filing, PBH was trading at $48.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $42.62 to $81.65. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PBH - Latest Insights

PBH
Aug 06, 2026, 6:15 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $52.97
Real-time Price: $51.53 info
Change: -$1.45 (-3%) info
Market Cap: $2.441B info
PBH
Aug 06, 2026, 6:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $52.97
Real-time Price: $51.53 info
Change: -$1.45 (-3%) info
Market Cap: $2.441B info
PBH
Aug 06, 2026, 6:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $52.97
Real-time Price: $51.53 info
Change: -$1.45 (-3%) info
Market Cap: $2.441B info
PBH
Jul 15, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $48.36
Real-time Price: $51.53 info
Change: +$3.16 (+7%) info
Market Cap: $2.441B info
PBH
Jul 06, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $49.42
Real-time Price: $51.53 info
Change: +$2.10 (+4%) info
Market Cap: $2.441B info